Pacira BioSciences (FRA:82P) Cyclically Adjusted FCF per Share: €1.73 (As of Mar. 2026)


FRA:82P Pacira BioSciences Inc FRA:82P
79 GF Score
Price €22.00
GF Value €25.64
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences Cyclically Adjusted FCF per Share?

Pacira BioSciences FRA:82P 79 Cyclically Adjusted FCF per Share is €1.73 as of Mar. 2026. GuruFocus rates FRA:82P with a GF Score™ of 79/100 and a GF Value™ of €25.64. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Pacira BioSciences's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.485. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €1.73 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pacira BioSciences's average Cyclically Adjusted FCF Growth Rate was 26.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 47.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Pacira BioSciences was 47.20% per year. The lowest was 47.20% per year. And the median was 47.20% per year.

As of today (2026-07-12), Pacira BioSciences's current stock price is €22.00. Pacira BioSciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €1.73. Pacira BioSciences's Cyclically Adjusted Price-to-FCF of today is 12.72.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pacira BioSciences was 742.18. The lowest was 8.93. And the median was 23.44.


Pacira BioSciences  (FRA:82P) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Pacira BioSciences's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=22.00/1.73
=12.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pacira BioSciences was 742.18. The lowest was 8.93. And the median was 23.44.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Pacira BioSciences Cyclically Adjusted FCF per Share Related Terms


Pacira BioSciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Cyclically Adjusted FCF per Share Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 0.54 0.96 1.46 1.54

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.42 1.35 1.48 1.54 1.73

FRA:82P vs ETON, AMPH, BIOA: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted Price-to-FCF falls into.


FRA:82P
79GF Score
Pacira BioSciences Inc FRA:82P
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacira BioSciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.485/330.2130*330.2130
=0.485

Current CPI (Mar. 2026) = 330.2130.

Pacira BioSciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.032 241.018 -0.044
201609 0.186 241.428 0.254
201612 0.316 241.432 0.432
201703 -0.089 243.801 -0.121
201706 -0.033 244.955 -0.044
201709 -0.171 246.819 -0.229
201712 0.247 246.524 0.331
201803 -0.157 249.554 -0.208
201806 0.227 251.989 0.297
201809 0.255 252.439 0.334
201812 0.405 251.233 0.532
201903 0.032 254.202 0.042
201906 0.433 256.143 0.558
201909 0.365 256.759 0.469
201912 0.461 256.974 0.592
202003 -0.011 258.115 -0.014
202006 -0.516 257.797 -0.661
202009 0.614 260.280 0.779
202012 0.593 260.474 0.752
202103 -0.018 264.877 -0.022
202106 0.357 271.696 0.434
202109 0.883 274.310 1.063
202112 0.273 278.802 0.323
202203 0.452 287.504 0.519
202206 0.326 296.311 0.363
202209 0.826 296.808 0.919
202212 0.751 296.797 0.836
202303 0.255 301.836 0.279
202306 0.711 305.109 0.770
202309 0.739 307.789 0.793
202312 0.609 306.746 0.656
202403 0.816 312.332 0.863
202406 0.949 314.175 0.997
202409 0.973 315.301 1.019
202412 0.641 315.605 0.671
202503 0.535 319.799 0.552
202506 0.178 322.561 0.182
202509 1.092 324.800 1.110
202512 0.864 324.054 0.880
202603 0.485 330.213 0.485

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €1.73 mean?
Pacira BioSciences (FRA:82P) has a Cyclically Adjusted FCF per Share of €1.73 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Cyclically Adjusted FCF per Share too high?
Pacira BioSciences' current Cyclically Adjusted FCF per Share is €1.73. Overall, Pacira BioSciences has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Cyclically Adjusted FCF per Share compare to ETON and AMPH?
Pacira BioSciences' Cyclically Adjusted FCF per Share of €1.73 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Cyclically Adjusted FCF per Share is €1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Cyclically Adjusted FCF per Share of €1.73. The stock's GF Value™ is €25.64, compared to a current price of €22.00 — trading 14.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €1.73. Pacira BioSciences' overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Cyclically Adjusted FCF per Share is €1.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.00 is trading 14.2% below its estimated GF Value™ of €25.64.

Key valuation signals for FRA:82P:

  • Cyclically Adjusted FCF per Share: €1.73
  • GF Value™: €25.64 vs. price of €22.00 (14.2% below fair value)
  • GF Score™: 79/100 with 8 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
79GF Score

Get the complete analysis for FRA:82P

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.00
Price
€25.64
GF Value